Document is current

Any future updates will be listed below

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; imlunestrant for breast cancer, tafasitamab for follicular lymphoma, atezolizumab for thymic carcinoma, retifanlimab for anal canal squamous cell carcinoma, and tagraxofusp for blastic plasmacytoid dendritic cell neoplasm

Crossref DOI link: https://doi.org/10.1007/s10147-025-02955-3

Published Online: 2026-01-08

Published Print: 2026-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark